JP2025503737A - Ａｐｏｌ１阻害剤及び使用方法 - Google Patents

Ａｐｏｌ１阻害剤及び使用方法 Download PDF

Info

Publication number
JP2025503737A
JP2025503737A JP2024542323A JP2024542323A JP2025503737A JP 2025503737 A JP2025503737 A JP 2025503737A JP 2024542323 A JP2024542323 A JP 2024542323A JP 2024542323 A JP2024542323 A JP 2024542323A JP 2025503737 A JP2025503737 A JP 2025503737A
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
halo
pharma
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542323A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503737A5 (https=
Inventor
パトリック サン テ リー，
トッド ジョナサン オーガスト ユーイング，
アダム ニール リード，
クリストファー ジョセフ シンズ，
ビロン ジャン，
サラ エム． ブロナー，
ジュニア， デイビッド ジョン モーガンズ
マールテン フック，
ビクトリア アン アシモン，
クリス ジーベンハウス，
アレクサンダー ウェイン シャメル，
Original Assignee
メイズ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイズ セラピューティクス， インコーポレイテッド filed Critical メイズ セラピューティクス， インコーポレイテッド
Publication of JP2025503737A publication Critical patent/JP2025503737A/ja
Publication of JP2025503737A5 publication Critical patent/JP2025503737A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • C07F9/5333—Arylalkane phosphine oxides or thioxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2024542323A 2022-01-18 2023-01-17 Ａｐｏｌ１阻害剤及び使用方法 Pending JP2025503737A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202263300592P 2022-01-18 2022-01-18
US63/300,592 2022-01-18
US202263311668P 2022-02-18 2022-02-18
US63/311,668 2022-02-18
US202263332553P 2022-04-19 2022-04-19
US63/332,553 2022-04-19
US202263400359P 2022-08-23 2022-08-23
US63/400,359 2022-08-23
US202263422341P 2022-11-03 2022-11-03
US63/422,341 2022-11-03
PCT/US2023/060787 WO2023141432A2 (en) 2022-01-18 2023-01-17 Apol1 inhibitors and methods of use

Publications (2)

Publication Number Publication Date
JP2025503737A true JP2025503737A (ja) 2025-02-04
JP2025503737A5 JP2025503737A5 (https=) 2026-01-27

Family

ID=87349294

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542323A Pending JP2025503737A (ja) 2022-01-18 2023-01-17 Ａｐｏｌ１阻害剤及び使用方法

Country Status (13)

Country Link
US (3) US11976067B2 (https=)
EP (1) EP4465982A4 (https=)
JP (1) JP2025503737A (https=)
KR (1) KR20240149461A (https=)
AU (1) AU2023208684A1 (https=)
CA (1) CA3248924A1 (https=)
CL (1) CL2024002165A1 (https=)
CO (1) CO2024010542A2 (https=)
IL (1) IL314330A (https=)
MX (1) MX2024008868A (https=)
PE (1) PE20250603A1 (https=)
TW (1) TW202339716A (https=)
WO (1) WO2023141432A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2024249254A2 (en) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
WO2025015106A2 (en) * 2023-07-11 2025-01-16 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use thereof
CN121793963A (zh) * 2023-07-11 2026-04-03 梅兹治疗公司 Apol1抑制剂和使用方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142859A1 (ja) * 2007-05-18 2008-11-27 Kowa Company, Ltd. 新規なスピロオキシインドール化合物及びこれを含有する医薬
WO2011101297A1 (en) * 2010-02-17 2011-08-25 F. Hoffmann-La Roche Ag Substituted spiroindolinones
JP2022515369A (ja) * 2018-12-17 2022-02-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びその使用方法
WO2022125524A1 (en) * 2020-12-07 2022-06-16 Lieber Institute, Inc. Compounds for inhibiting inositol hexakisphosphate kinase (ip6k) and methods of use thereof
JP2023512213A (ja) * 2020-01-29 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤およびこれを使用する方法
JP2023530271A (ja) * 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
WO2023194895A1 (en) * 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
JP2024544060A (ja) * 2021-11-30 2024-11-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法
JP2025505645A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法
JP2025505647A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
EP0450761A1 (en) 1990-03-02 1991-10-09 Merck & Co. Inc. Spirocyclic oxytocin antagonists
CA2037357A1 (en) 1990-03-02 1991-09-03 Ben E. Evans Methods for using spirocyclic oxytocin antagonists
US5731317A (en) 1995-03-10 1998-03-24 Merck & Co., Inc. Bridged piperidines promote release of growth hormone
US6013652A (en) 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
US6916822B2 (en) 2000-02-18 2005-07-12 Meiji Seika Kaisha, Ltd. Phenoxyalkylamine derivatives useful as opioid δ receptor agonists
DE10306250A1 (de) 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
CA2599925A1 (en) 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
EP2316829A1 (en) 2005-12-21 2011-05-04 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
EP2023924B1 (en) 2006-05-18 2016-08-03 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
EP2027106A2 (en) 2006-06-13 2009-02-25 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2009061676A2 (en) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonists of pgd2 receptors
JP5451646B2 (ja) 2008-02-27 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
CA2779958A1 (en) 2008-11-06 2010-05-14 University Of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
US9023355B2 (en) 2010-04-13 2015-05-05 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating renal disease
CN101851237B (zh) 2010-06-18 2012-10-17 南方医科大学 一种螺环化合物及其制备方法和应用
MX2013009393A (es) 2011-02-18 2013-08-29 Vertex Pharma Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
CN102516263B (zh) 2011-10-25 2015-04-08 南方医科大学 一种螺三环类化合物及其制备方法、以及含该类化合物的药物组合物及其应用
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
WO2016022644A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016071293A2 (en) 2014-11-03 2016-05-12 Iomet Pharma Ltd Pharmaceutical compound
TW201718010A (zh) 2015-06-19 2017-06-01 健臻公司 治療原發性局部節段性腎小球硬化症之方法
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2019115586A1 (en) 2017-12-12 2019-06-20 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
IL278785B2 (en) 2018-05-22 2025-03-01 Ionis Pharmaceuticals Inc Modulators of apol1 expression
IL286481B2 (en) 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
EP3960736A4 (en) 2019-04-26 2023-04-19 Generos Biopharma Ltd. HETEROCYCLIC COMPOUND, ITS APPLICATION AND COMPOSITION WITH IT
KR20220118527A (ko) 2019-12-23 2022-08-25 제넨테크, 인크. 아포지질단백질 l1-특이적 항체 및 이용 방법
TW202140480A (zh) 2020-01-15 2021-11-01 日商拉夸里亞創藥股份有限公司 作為crhr2拮抗劑之螺雜環衍生物
US20210246121A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Methods of treating apol-1 dependent focal segmental glomerulosclerosis
JP2023524563A (ja) 2020-05-07 2023-06-12 ラムバム メド－テック リミテッド Ａｐｏｌ１－関連疾患の治療に使用するための組成物
CN115867532A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1的抑制剂及其用途
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
IL301574A (en) 2020-09-25 2023-05-01 Neuropore Therapies Inc Modulators of tlr signaling modulator compounds, compositions comprising same and uses thereof
KR20230110544A (ko) 2020-11-19 2023-07-24 머크 샤프 앤드 돔 엘엘씨 혈장 칼리크레인 억제제
CN116997546A (zh) 2021-02-19 2023-11-03 梅兹治疗公司 Apol1抑制剂及使用方法
EP4351569A4 (en) 2021-05-28 2025-04-16 D.E. Shaw Research, LLC Spiroindolinone compounds as kv1.3 potassium shaker channel blockers
US20230119114A1 (en) 2021-08-26 2023-04-20 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitors and methods of using same
AR127625A1 (es) 2021-11-10 2024-02-14 Nurix Therapeutics Inc Degradadores bifuncionales inhibidores de la quinasa del progenitor hematopoyético y usos terapeuticos de los mismos
WO2023091561A1 (en) 2021-11-18 2023-05-25 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
CN118946349A (zh) * 2022-01-18 2024-11-12 梅兹治疗公司 Apol1抑制剂及使用方法
CR20240344A (es) * 2022-01-18 2024-12-09 Maze Therapeutics Inc Inhibidores de apol1 y métodos de uso
AU2023219516A1 (en) 2022-02-08 2024-08-22 Vertex Pharmaceuticals Incorporated 2-methyl-4-phenylpiperidin-4-ol derivatives as inhibitors of apol1 and methods of using same
EP4476228A1 (en) 2022-02-08 2024-12-18 Vertex Pharmaceuticals Incorporated 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
CN119731179A (zh) 2022-03-25 2025-03-28 密歇根大学董事会 Ikzf2降解剂及其用途
WO2024249254A2 (en) 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Methods of using apol1 inhibitors
CN121793963A (zh) 2023-07-11 2026-04-03 梅兹治疗公司 Apol1抑制剂和使用方法
WO2025015106A2 (en) 2023-07-11 2025-01-16 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use thereof
WO2025019479A1 (en) 2023-07-17 2025-01-23 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142859A1 (ja) * 2007-05-18 2008-11-27 Kowa Company, Ltd. 新規なスピロオキシインドール化合物及びこれを含有する医薬
WO2011101297A1 (en) * 2010-02-17 2011-08-25 F. Hoffmann-La Roche Ag Substituted spiroindolinones
JP2022515369A (ja) * 2018-12-17 2022-02-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びその使用方法
JP2023512213A (ja) * 2020-01-29 2023-03-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤およびこれを使用する方法
JP2023530271A (ja) * 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤及びこれを使用する方法
WO2022125524A1 (en) * 2020-12-07 2022-06-16 Lieber Institute, Inc. Compounds for inhibiting inositol hexakisphosphate kinase (ip6k) and methods of use thereof
JP2024544060A (ja) * 2021-11-30 2024-11-27 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１のスピロ環式阻害剤およびこれを使用する方法
JP2025505645A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１の阻害剤としてのスピロピペリジン誘導体およびその使用方法
JP2025505647A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法
WO2023194895A1 (en) * 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1

Also Published As

Publication number Publication date
US12344610B2 (en) 2025-07-01
WO2023141432A3 (en) 2023-09-21
EP4465982A4 (en) 2025-11-26
TW202339716A (zh) 2023-10-16
CA3248924A1 (en) 2023-07-27
US20250282781A1 (en) 2025-09-11
EP4465982A2 (en) 2024-11-27
CL2024002165A1 (es) 2025-01-24
IL314330A (en) 2024-09-01
KR20240149461A (ko) 2024-10-14
PE20250603A1 (es) 2025-02-26
US20240400565A1 (en) 2024-12-05
CO2024010542A2 (es) 2024-08-08
US11976067B2 (en) 2024-05-07
AU2023208684A1 (en) 2024-09-05
WO2023141432A2 (en) 2023-07-27
MX2024008868A (es) 2024-09-23
US20230265096A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US12344610B2 (en) APOL1 inhibitors and methods of use
US20250205219A1 (en) Targeted degradation of vav1
US8722692B2 (en) Compounds and compositions as Syk kinase inhibitors
TW202509031A (zh) Ｃｄｋ抑制劑萘啶化合物
EA035757B1 (ru) Производные дигидрохинолин-2-она
EA022850B1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
JP2016500694A (ja) ２−アミノピリジン化合物
EP4577549A1 (en) Compounds and methods for modulating her2
TW201811785A (zh) 7-經取代之1-芳基萘啶-3-甲醯胺及其用途
US20230339886A1 (en) Rev-erb agonists for the treatment of th17-mediated inflammatory disorders
TW202511261A (zh) 使用ａｐｏｌ１抑制劑之方法
CN118946349A (zh) Apol1抑制剂及使用方法
TW202517644A (zh) Ａｐｏｌ１抑制劑及使用方法
TW202517642A (zh) Ａｐｏｌ１抑制劑及其使用方法
TW202510867A (zh) Ａｐｏｌ１抑制劑及使用方法
OA22045A (en) APOL1 inhibitors and methods of use.
EA049911B1 (ru) Ингибиторы apol1 и способы их применения
HK40119446A (zh) Apol1抑制剂及使用方法
JP2022553261A (ja) 寄生虫病の処置のための化合物及び組成物
RU2778641C2 (ru) Производные конденсированной циклической мочевины в антагонист crhr2
TW202502748A (zh) 用於調節stat3之化合物及方法
TW202542138A (zh) 與含ｐａｔａｔｉｎ樣磷脂酶結構域蛋白３ＩＭ結合的化合物及其用於治療肝病之用途
CN119585272A (zh) 咪唑并吡啶化合物、其制备及其治疗用途
IL325136A (en) Pyrazolo-pyrimidinone compounds for use in methods for inhibiting kinase week1 a

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260116

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260413